Chaabane A, Aouam K, Boughattas N A, Chakroun M
Laboratoire de pharmacologie, faculté de médecine, rue Avicenne, 5019 Monastir, Tunisie.
Med Mal Infect. 2009 May;39(5):278-87. doi: 10.1016/j.medmal.2008.09.011. Epub 2008 Nov 5.
Allergic reactions to penicillins have been reported since the 1950s, shortly after their introduction as therapeutic agents. An increasing number of reported anaphylactic reactions and other adverse effects proved this to be a serious public health problem. Fifty years later, betalactam-induced hypersensitivity is the most frequent cause of drug reaction and has been the source of a great number of publications. Clinically, betalactam-induced allergic reactions may be immediate or non-immediate according to the time interval between drug intake and the occurrence of symptoms. The diagnosis of betalactam hypersensitivity is based on skin tests methods, in vitro tests and drug provocation test. There are three classical methods for skin testing: prick, intradermal, and patch. These tests are still the most sensitive techniques. In vitro tests, mainly based on the quantification of IgE antibodies to betalactams by immunoassay (Fluorescent Enzyme Immunoassay [FEIA]), may sometimes yield useful complementary information. Drug provocation tests must be performed with the required caution and the adequate indication. Algorithms are available for both immediate and non-immediate reactions to provide a practical approach for patient evaluation. They are based on the following data: clinical history, skin tests, FEIA, and drug provocation tests. Finally, cross reactivity between betalactams has been reported, especially between penicillins and cephalosporins. Their frequency was long over-estimated, but recent evidence, indicates that cross reactivity between betalactams has become rare. Administration of cephalosporins in patients with a history of penicillin allergy requires performing skin testing with penicillin, the probably allergenic drug, and the cephalosporin to be prescribed.
自20世纪50年代青霉素作为治疗药物被引入后不久,就有关于青霉素过敏反应的报道。越来越多报告的过敏反应和其他不良反应证明这是一个严重的公共卫生问题。五十年后,β-内酰胺诱导的超敏反应是药物反应最常见的原因,并且一直是大量出版物的主题。临床上,根据药物摄入与症状出现之间的时间间隔,β-内酰胺诱导的过敏反应可能是速发型或非速发型。β-内酰胺超敏反应的诊断基于皮肤试验方法、体外试验和药物激发试验。皮肤试验有三种经典方法:点刺试验、皮内试验和斑贴试验。这些试验仍然是最敏感的技术。体外试验主要基于通过免疫测定(荧光酶免疫测定[FEIA])对β-内酰胺的IgE抗体进行定量,有时可能会产生有用的补充信息。药物激发试验必须谨慎进行并有适当的指征。对于速发型和非速发型反应都有可用的算法,为患者评估提供实用方法。它们基于以下数据:临床病史、皮肤试验、FEIA和药物激发试验。最后,已报道β-内酰胺之间存在交叉反应,尤其是青霉素和头孢菌素之间。它们的发生率长期被高估,但最近的证据表明,β-内酰胺之间的交叉反应已变得罕见。有青霉素过敏史的患者使用头孢菌素时,需要用可能具有致敏性的药物青霉素以及待处方的头孢菌素进行皮肤试验。